0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Item 9 Labs
Its shares trade under the ticker INLB. It has been listed since 3 November 2011. In the fiscal year to 30 September 2022, it reported revenue of $21.8m and a net loss of $31.1m. At that date it held total assets of $110.8m and shareholders' equity of $62.0m.
Item 9 Labs Corp. engages in creating cannabis health solutions for the modern consumer. The company is headquartered in Phoenix, Arizona. The company went IPO on 2011-11-03. The firm targets customers, such as compassionate sleeping partners, individuals with chronic sinus issues, individuals that suffer from chronic sleep disorders and individuals with allergies throughout the United States, Canada, Asia and Europe. The firm's products provide consumers with safe methods to control their own personal breathing environment. The firm's filtered product also contains 3M filtration media for allergy sufferers. The AIR nasal dilator is made from latex-free/adhesive-free hypoallergenic medical grade material. AIR nasal products are manufactured with or without 3M's Filtration Media depending on the whether the product is designed to enhance nasal breathing alone or in addition, filter the air of particulate matter, including allergens and bacteria.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Nov 2011
- Employees
- 65
- Website
- investor.airwarelabs.com ↗
Leadership
Pay as last reported
- Mr. Christopher WolvenChief Operating Officer$358,041
- Mr. Eric KutscherIndependent Director$124,555
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Item 9 Labs Corp has a strong market position as a provider of high-quality cannabis products.
- The company has established a solid distribution network across multiple states.
- Item 9 Labs Corp has a dedicated and experienced team with expertise in cannabis cultivation and product development.
- The company has a strong brand reputation and brand recognition among consumers.
Weaknesses
- Item 9 Labs Corp may face challenges in complying with evolving cannabis regulations.
- The company's dependence on a limited number of suppliers or partners may pose risks to its supply chain.
- Item 9 Labs Corp may need to invest in infrastructure and technology to support its growth plans.
- The company's profitability can be affected by fluctuations in cannabis prices and market demand.
Opportunities
- The legalization of cannabis in more states and countries opens up new market opportunities for Item 9 Labs Corp.
- The growing acceptance of cannabis for medical and wellness purposes increases the potential customer base for the company.
- Item 9 Labs Corp can expand its product offerings to cater to emerging trends and consumer preferences in the cannabis industry.
- The company can explore strategic partnerships or acquisitions to strengthen its market position and expand its reach.
Threats
- Increased competition in the cannabis industry poses a threat to Item 9 Labs Corp's market share and pricing power.
- Changes in government regulations or policies related to cannabis can impact the company's operations and profitability.
- The negative perception and stigma associated with cannabis can limit consumer adoption and growth potential for Item 9 Labs Corp.
- The company may face challenges in securing financing or capital for its expansion plans in a highly regulated industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.